References
1. Cookson D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J AntimicrobChemother1998; 41:11-8.
2. Zierdt CH. Long term Staphylococcus aureus carrier state in hospital patients. J ClinMicrobiol1982; 16:517-20.
3. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995; 31:13–24.
4. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11–6.
5. Corne P, Marchandin H, Jonquet O, Campos J, Banuls AL. Molecular evidence that nasal carriage of Staphylococcus aureus plays a role in respiratory tract infections of critically ill patients. J ClinMicrobiol2005; 43:3491–3.
6. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM, Jr., Storch GA, Coopersmith CM, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis. 2007;45(5):541-7.
7. Sousa-Junior FC, Silva-Carvalho MC, Fernandes MJ, Vieira MF, Pellegrino FL, Figueiredo AM, et al. Genotyping of methicillin-resistant Staphylococcus aureus isolates obtained in the Northeast region of Brazil. Braz J Med Biol Res. 2009;42(10):877-81.
8. Kluytmans J, Belkum A, Verbrugh H. Nasal Carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. ClinMicrobiol Rev1997; 10: 505-520.
9. Palepou MF, Johnson AP, Cookson BD, et al. Evaluation of disc diffusion and E-test for determining the susceptibility of Staphylococcus aureus to mupirocin. J AntimicrobChemother 1998:42:577–83.
10. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin:an evidenced-based review. Clin Infect Dis. 2003; 37:933-8.
11. Rahaman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus. Lancet. 1987; 2:387-8.
12. Morehouse E, Fenelon L, Hone R. Staphylococcus aureus sensitivity to various antibiotics- a national survey of Ireland 1993. Irish J Med Sci 1996; 165:40-3.
13. Upton A, Lang S, Hefferman H. Mupirocin and Staphylococcus aureus: A recent paradigm of emerging antibiotic resistance of Antimicrobial Chemother 2003; 51:613-7.
14. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, SarubbiFA.The epidemiology of mupirocin resistance among methicillin-resistant Staphyloco-ccus aureus at a veteran's affair hospital. Infect Control HospEpidemiol 2000; 21:459-64.
15. Udo, E. L. Jacob,B. Mathew. 2001. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J. Med. Microbiol.50:909-915.
16. Christine Seah, David C. Alexander, Lisa Louie, Andrew Simor, Donald E. Low, Jean Longtin and Roberto G. Melano. MupB, a New High-Level Mupirocin Resistance Mechanism in Staphylococcus aureus. Antimicrob. Agents Chemother. 2012, 56(4):1916.
17. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidinegluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44:178–85.
18. Clinical and laboratory standard institute (2012). Performance standards for antimicrobial disc susceptibility tests, twentieth supplement. 32(3) M100- S21.
19. Finlay JE, Millar LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997; 41: 1137-9.
20. Yazgi H, Ertek M, Ozbek A, Kadanali A. Nasal carriage of Staphylococcus aureus in hospital personnel and the normal population and antibiotic resistance of the isolates. Mikrobiyol Bul. 2003 Apr-Jun; 37(2-3):137-42.
21. Halablab MA, Hijazi SM, Fawzi MA, Araj GF. Staphylococcus aureus nasal carriage rate and associated risk factors in individuals in the community. Epidemiol Infect. 2010; 138(5):702-6.
22. Adebayo O Shittu, Edet E Udo and Johnson Lin. Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. BMC Infectious Diseases 2009, 9:10
23. Hurdle JG, O’Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J AntimicrobChemother 2005; 56:1166–8.
24. Bastos MC, Mondino PJ, Azevedo ML, Santos KR, Giambiagi-deMarval M. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur J ClinMicrobiol Infect Dis 1999; 18:393–8.
25. Tara Babu, VioletaRekasius, Jorge P. Parada, Paul Schreckenberger, Malliswari Challapalli. Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus-Colonized Patients at Admission to a Tertiary Care Medical Center.J Clin Microbiol. Jul 2009; 47(7): 2279–2280.
26. Jeffrey C. Jones,Theodore J. Rogers,Peter Brookmeyer,William Michael Dunne, Jr.,Gregory A. Storch, Craig M. Coopersmith et al.Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit. Clinical Infectious Diseases 2007; 45:541–7
27. Vivoni AM, Santos KR, de-Oliveira MP, et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 2005; 26:662–7.